Metastatic colorectal cancer remains the second leading cause of cancer-related mortality globally, but treatment options are generally limited to RAS mutation status for anti-EGFR therapies. Researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne developed a method to grow organoids from patient-derived tumor samples that achieved 83% accuracy in predicting patient responses to different therapies. Read More
Researchers from Johns Hopkins University and affiliated organizations have published details on the discovery and preclinical characterization of a purine antimetabolite, Pro-905, which is being developed for the treatment of malignant peripheral nerve sheath tumors (MPNST). Read More
Iama Therapeutics Srl has obtained clinical trial application (CTA) clearance from the Italian Medicines Agency (AIFA) to initiate a first-in-human phase I study of IAMA-6, an orally administered small-molecule therapeutic targeting NKCC1 for the treatment of autism and epilepsy. Read More
In a study published in Antiviral Research, researchers from the Max Planck Institute for Multidisciplinary Sciences and collaborators have presented optimized nanobodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Read More
Researchers have developed a novel chronic lymphocytic leukemia (CLL) murine model that expresses human BCL2 in B cells under the TCL1 promoter control, named TBC. Read More
The FDA has awarded orphan drug designation to Ocelot Bio Inc.'s lead candidate OCE-205 for the treatment of ascites due to all etiologies except cancer. Ocelot Bio plans to initiate clinical studies of OCE-205 in refractory ascites next year. Read More
Jazz Pharmaceuticals plc has disclosed macrocyclic orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia, narcolepsy and sleep disorders. Read More
Sudo Biosciences Inc. has closed a $116 million series B financing, with the funding raised to be used to advance two investigational TYK2 candidates into the clinic in 2024. Read More
Both CD47 and CD24 are antiphagocytic factors overexpressed in several cancers such as non-small-cell lung cancer, and breast and ovarian cancer. Read More
Xiamen University has synthesized oligopeptides targeting β2-microglobulin (B2M) reported to be useful for the treatment of cancer and Alzheimer’s disease. Read More
Researchers at Centre Hospitalier de Université de Montréal and University of Pennsylvania have identified compounds reported to be useful for the treatment of HIV-1 infection. Read More
MYB is a transcription factor essential for cell proliferation and differentiation, and is regarded as a target for cancer therapy because it is overexpressed in many different tumor types such as adenoid cystic carcinoma (ACC), acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia, among others. Read More
University of Minnesota has divulged nonstructural protein 14 (NSP14) (SARS-CoV-2) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection. Read More
Korea Institute of Science and Technology has described nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators acting as nitric oxide (NO) production inhibitors and antioxidants reported to be useful for the treatment of acute respiratory distress syndrome, chronic kidney disease, chronic obstructive pulmonary disease, kidney fibrosis, nonalcoholic fatty liver disease, viral hepatitis, Parkinson’s disease and Alzheimer’s disease. Read More
Immunoscape Pte Ltd. and Mink Therapeutics Inc. have entered into a collaboration agreement to discover and develop next-generation T-cell receptor (TCR) therapies against novel targets in solid tumors. Read More
Are you trying to stay on top of developments in CAR T therapies? Drug resistance? Emerging compounds? Updates from certain regulatory agencies? Want to be the first to learn about new biomarkers or business deals? You can still find these articles in the daily BioWorld e-newsletters or on the website, but if you’re laser-focused on a specific topic, we have a way to highlight the news you need as it happens, whether we’ve published a full-length feature story or a brief update. You asked and we listened. Now, in addition to the daily news lineup, you can create topic alerts to be delivered directly to your inbox or via an RSS reader. It’s easy to set up. Instructions can be found here: https://www.bioworld.com/featured-feeds. Happy holidays! Read More
